United Therapeutics (UTHR) reported a Q4 adjusted EPS of $2.88, beating the estimate $1.51 by $1.37. Revenues came in at $289 million, up 18.5% from $243.8 million a year earlier, missing estimates of $295 million. However, without the earnings adjustment, the company actually reported a loss of $30 million or 60 cents per share. The main reason was share-based compensation, which totaled almost $100 million for the quarter, reflecting the rise in UTHR stock price (options and shares given to employees have to marked-to-market every quarter). The CEO, Martine Rothblatt was very optimistic regarding 2014, because the company "will realize it's original founding purpose". She is referring to Orenitram, a pill for the pulmonary hypertension market approved by FDA in December 2013 and expected to be launched in the middle of 2014.
The stock was down almost 4% yesterday, but I remain bullish, as they have a market leadership in PH and the valuations are still reasonable (P/E 18, P/S 4.7) given their 20% growth.
Pegasystems (PEGA) ended the 4th quarter with a profit of 61 cents per share ($24 million), down from 65 cents a year earlier ($25.19 million) but 14 cents higher than the $0.47 estimate. Revenues grew 8% to $155.58, but missed expectations of $158 million. The company raised guidance for 2014, projecting revenues of $580 million and EPS of $1.56, higher than analyst estimates of $573 million and $1.48.
PEGA stock was up 6% in after-hours, I'm still holding it although I might sell the entire position if I find a better opportunity, their growth seems to be slowing down.
The stock was down almost 4% yesterday, but I remain bullish, as they have a market leadership in PH and the valuations are still reasonable (P/E 18, P/S 4.7) given their 20% growth.
Pegasystems (PEGA) ended the 4th quarter with a profit of 61 cents per share ($24 million), down from 65 cents a year earlier ($25.19 million) but 14 cents higher than the $0.47 estimate. Revenues grew 8% to $155.58, but missed expectations of $158 million. The company raised guidance for 2014, projecting revenues of $580 million and EPS of $1.56, higher than analyst estimates of $573 million and $1.48.
PEGA stock was up 6% in after-hours, I'm still holding it although I might sell the entire position if I find a better opportunity, their growth seems to be slowing down.
RSS Feed